Previous 10 | Next 10 |
Galapagos press release ( NASDAQ: GLPG ): 9M GAAP EPS of -€0.16. Revenue of €410.2M (+29.0% Y/Y). Clear path forward for accelerated growth and value creation Reshape innovation model and build fit-for-purpose organization in key strategic ...
Galapagos ( NASDAQ: GLPG ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, after market close. The consensus EPS Estimate is -$1.21 and the consensus Revenue Estimate is $106.87M Over the last 3 months, EPS estimates have seen 0 upward revisio...
Summary Galapagos has had a new CEO since April 2022. The company's new strategy is taking shape with some research programs scrapped and small assets acquired. Jyseleca is growing rapidly and has a way to go. Meanwhile, Galapagos trades at a sizeable discount to cash. ...
Summary David Einhorn's 13F stock portfolio value decreased from $1.57B to $1.29B this quarter. Greenlight increased Atlas Air Worldwide, Kyndryl Holdings, and Victoria’s Secret while decreasing Teck Resources, Change Healthcare, Chemours, and International Seaways. They al...
Belgian pharmaceutical firm Galapagos ( NASDAQ: GLPG ) on Monday said the European Union's human medicines committee had recommended amending the label of its inhibitor Jyseleca to remove a warning regarding its effect on testicular function. The European Medicines Agency'...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This year will probably go down as the roughest year for investors since the financial recession in 2008. The S&P 500 has shed more than 20% of its value year-to-date as inflation and interest rates weigh down the equ...
Galapagos ( NASDAQ: GLPG ) was downgraded by Morgan Stanley to Equal Weight from Overweight with price target cut to $61 from $80 citing a positive but slow transformation. The SA Quant Rating on GLPG is Buy , which takes into account factors such as growt...
Galapagos NV (GLPG) Q2 2022 Earnings Conference Call August 5, 2022 08:00 ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer ...
Galapagos press release ( NASDAQ: GLPG ): 1H GAAP EPS of -€0.49. Revenue of €274M Following the acquisitions of CellPoint and AboundBio, we revised our cash burn guidance for full year 2022 from €450-€490 million to €480-€520 m...
First half-year 202 2 financial results : Jyseleca ® net sales reached €35.4 million Group revenues of €274.0 million Operating loss of €97.5 million Cash and c ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...